“Appendix 3B New issue announcement, application for quotation of additional securities and agreement” has been released by Imagion Biosystems. Read Appendix 3B here.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)